The UC Davis retrospective cohort of 3,811 out-of-hospital cardiac arrest cases from the California Resuscitation Outcomes Consortium (2021-2022) reports a 2.8% absolute survival increase to discharge with EMS naloxone, alongside gains in ROSC (+3.3%) and favorable neurology (+3.2%). This observational design, however, cannot establish causation; patients receiving naloxone were more likely to have suspected drug-related arrests, introducing selection bias that the authors adjusted for yet could not fully eliminate. Stronger benefits (8-9% survival lift) appeared in the drug-suspected subgroup, aligning with rising opioid-driven OHCA incidence documented in CDC data through 2024. The study correctly flags weakening of the association when epinephrine was required, hinting that late administration or prolonged arrest reduces utility. Prior AHA guidelines explicitly labeled this an evidence gap; a 2023 multicenter observational analysis in Resuscitation (n=1,245) similarly found ROSC improvement but no neurologic benefit after multivariable adjustment, underscoring inconsistent signals across datasets. No industry conflicts are disclosed here, yet real-world EMS protocol changes would require RCTs to rule out residual confounding before altering epinephrine-first algorithms.